Multinationals, Patients Benefit From New Approvals As China Speeds Reviews
The China FDA’s new priority reviews and faster approval procedures for innovative drugs are beginning to bear fruit, with multinationals and patients among the first beneficiaries from recent clearances from two novel cancer drugs in this large emerging market.
You may also be interested in...
AstraZeneca’s lung cancer treatment appears to have made significant regulatory headway in Asia. Amid its recent record fast approval in China, Tagrisso also appears to have inched closer to potential clearance in India after a key expert panel exempted it from local trial requirements.
China continues to be the brightest star in AstraZeneca's emerging markets firmament amid some "softness" in other countries, and the UK group sees attractive prospects in the country for some of its innovative branded products.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.